Elucent Medical, a company specialising in guided surgical technologies, has announced that its EnVisio X1™ In-Body Spatial Intelligence™ System has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
This recognition supports the company’s continued focus on advancing real-time localisation and navigation technologies for soft tissue surgery, particularly in the treatment of cancer.
The EnVisio X1 System is designed to work smoothly within current surgical workflows and introduces a ‘smart’ marker called SmartClip®, which can be implanted through the skin or via bronchoscopy.
Unlike traditional markers, SmartClips are designed to remain in the body permanently. This flexibility helps reduce scheduling issues and logistical challenges ahead of surgery.
During an operation, the EnVisio SmartSensor X™, attached to a surgical stapler, tracks both the SmartClip and the stapler itself. This tracking is done wirelessly, providing real-time three-dimensional guidance to the surgeon.
The technology can support video-assisted and robotic-assisted procedures, offering a higher level of accuracy during soft tissue excisions in areas such as the thoracic and abdominal cavities. It is expected to reduce the chances of positive surgical margins and the need for additional surgeries, potentially improving patient outcomes.
The EnVisio X1 platform is still under development and has not yet received full FDA clearance. It is currently not available for sale or clinical use in the United States.
Soft tissue cancers, including those affecting the lungs, liver, colon, and lymphatic system, remain among the most challenging and life-threatening forms of the disease. These types of cancer are often detected in later stages, which limits treatment options and reduces survival rates. Enhancing surgical accuracy and efficiency is a key step in addressing this challenge.
The FDA Breakthrough Devices Programme aims to speed up the development and review process for technologies that may offer significant benefits for patients with serious or life-threatening conditions. Through this programme, Elucent will work closely with the FDA to advance the EnVisio X1 platform toward eventual regulatory approval and commercial use.
The system is intended for real-time, non-imaging-based localisation and surgical navigation of SmartClip markers and tracked instruments during soft tissue removal. It aims to provide accurate, intraoperative guidance to help surgeons navigate more effectively and treat patients with greater precision.
